Mark J. Bartlett
17Patents
4h-index
58Co-inventors
59Inventor score
Filing activity: Feb 20, 2009 → Mar 11, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7939531B2 | Pyrrolopyrazine kinase inhibitors | Chemistry; Metallurgy | 59 | Active |
| US11845755B2 | Compounds and methods for treatment of viral infections | Chemistry; Metallurgy | 6 | Active |
| US11851438B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | Chemistry; Metallurgy | 6 | Active |
| US11780844B2 | Compounds and methods for treatment of viral infections | Chemistry; Metallurgy | 5 | Active |
| US11203591B2 | Substituted 6-azabenzimidazole compounds | Chemistry; Metallurgy | 4 | Active |
| US11071730B2 | Substituted 6-azabenzimidazole compounds | Chemistry; Metallurgy | 4 | Active |
| US11040033B2 | Therapeutic heterocyclic compounds | Chemistry; Metallurgy | 1 | Active |
| US9951065B2 | Benzimidazole and imadazopyridine carboximidamide compounds | Chemistry; Metallurgy | 1 | Active |
| US12180217B2 | Compounds and methods for treatment of viral infections | Chemistry; Metallurgy | 1 | Active |
| US11897878B2 | Substituted 6-azabenzimidazole compounds | Chemistry; Metallurgy | 1 | Active |
| US11925631B2 | Substituted 6-azabenzimidazole compounds | Chemistry; Metallurgy | 1 | Active |
| US11919869B2 | CD73 compounds | Human Necessities | 0 | Active |
| US12110294B2 | CD73 compounds | Emerging Cross-Sectional Technologies | 0 | Active |
| US11098027B2 | Therapeutic heterocyclic compounds | Human Necessities | 0 | Active |
| US11229638B2 | Therapeutic heterocyclic compounds | Chemistry; Metallurgy | 0 | Active |
| US11186579B2 | Therapeutic heterocyclic compounds | Human Necessities | 0 | Active |
| US12258346B2 | Substituted 6-azabenzimidazole compounds | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.